Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 33, 2020 - Issue 4
Submit an article Journal homepage
1,579
Views
1
CrossRef citations to date
0
Altmetric
Review Articles

The dynamic treatment of SARS-CoV-2 disease

Uriel Sandkovskya Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas;b Division of Infectious Diseases, Baylor University Medical Center, Dallas, TexasCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9077-3426
, MD, MSORCID Icon,
Peter Colleyc Department of Pharmacy, Baylor University Medical Center, Dallas, TexasORCID Iconhttps://orcid.org/0000-0003-1415-8602
, PharmDORCID Icon,
Teena Samc Department of Pharmacy, Baylor University Medical Center, Dallas, Texas
, PharmD,
Ariel M. Modrykamiena Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas;d Medical Intensive Care Unit, Baylor University Medical Center, Dallas, Texas
, MD &
Mezgebe Berhea Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas;b Division of Infectious Diseases, Baylor University Medical Center, Dallas, Texas
, MD
Pages 572-579 | Received 08 May 2020, Accepted 05 Jun 2020, Published online: 23 Jun 2020

  • Jin Y , Yang H , Ji W , et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses . 2020;12(4):372. doi:10.3390/v12040372.
  • Fu Y , Cheng Y , Wu Y. Understanding SARS-CoV-2–mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin . 2020. doi:10.1007/s12250-020-00207-4.
  • Ye Q , Wang B , Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J Infect . 2020;80(6):607–613. doi:10.1016/j.jinf.2020.03.037.
  • Sanders JM , Monogue ML , Jodlowski TZ , Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA . 2020; doi:10.1001/jama.2020.6019.
  • Bhimraj A , Morgan RL , Shumaker AH , et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis . 2020;ciaa478. doi:10.1093/cid/ciaa478.
  • Wu Z , McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA . 2020;323(13):1239. doi:10.1001/jama.2020.2648.
  • Alhazzani W , Møller MH , Arabi YM , et al. Surviving Sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med . 2020;46(5):854–887. doi:10.1007/s00134-020-06022-5.
  • Wang Y , Wang Y , Chen Y , Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol . 2020;92(6):568–576. doi:10.1002/jmv.25748.
  • Chu CM , Cheng VC , Hung IF , et al ; HKU/UCH SARS Study Group . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax . 2004;59(3):252–256. doi:10.1136/thorax.2003.012658.
  • de Wilde AH , Jochmans D , Posthuma CC , et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother . 2014;58(8):4875–4884. doi:10.1128/AAC.03011-14.
  • Cao B , Wang Y , Wen D , et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med . 2020;382(19):1787–1799. doi:10.1056/NEJMoa2001282.
  • Devaux CA , Rolain JM , Colson P , Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents . 2020;55(5):105938. doi:10.1016/j.ijantimicag.2020.105938.
  • Liu J , Cao R , Xu M , et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov . 2020;6(1):16. doi:10.1038/s41421-020-0156-0.
  • Taccone FS , Gorham J , Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med . 2020;S2213-2600(20)30172-7. doi:10.1016/S2213-2600(20)30172-7.
  • Gautret P , Lagier JC , Parola P , et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis . 2020;34:101663. doi:10.1016/j.tmaid.2020.101663.
  • Magagnoli j , Narendran S , Pereira F , et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. Med . 2020. doi:10.1016/j.medj.2020.06.001.
  • Rosenberg ES , Dufort EM , Udo T , et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA . 2020. doi:10.1001/jama.2020.8630.
  • Delang L , Abdelnabi R , Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res . 2018;153:85–94. doi:10.1016/j.antiviral.2018.03.003.
  • Furuta Y , Komeno T , Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci . 2017;93(7):449–463. doi:10.2183/pjab.93.027.
  • Siegel D , Hui HC , Doerffler E , et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem . 2017;60(5):1648–1661. doi:10.1021/acs.jmedchem.6b01594.
  • Wang M , Cao R , Zhang L , et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res . 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0.
  • Zhai P , Ding Y , Wu X , Long J , Zhong Y , Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents . 2020;55(5):105955. doi:10.1016/j.ijantimicag.2020.105955.
  • Agostini ML , Andres EL , Sims AC , et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio . 2018;9(2):e00221–18. doi:10.1128/mBio.00221-18.
  • Holshue ML , DeBolt C , Lindquist S , et al; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med . 2020;382(10):929–936. doi:10.1056/NEJMoa2001191.
  • Grein J , Ohmagari N , Shin D , et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med . 2020;NEJMoa2007016. doi:10.1056/NEJMoa2007016.
  • Wang Y , Zhang D , Du G , et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet . 2020. doi:10.1016/S0140-6736(1020)31022-31029.
  • Beigel JH , Tomashek KM , Dodd LE , et al ; ACTT-1 study group members . Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med . 2020;NEJMoa2007764. doi:10.1056/NEJMoa2007764.
  • Hinton DM. Letter to A. Rhoades, Gilead sciences, granting emergency use authorization from the US Food and Drug Administration for remdesivir. https://www.fda.gov/media/137564/download. Published May 1, 2020.
  • Goldman JD , Lye DCB , Hui DS , et al ; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med . 2020;NEJMoa2015301. doi:10.1056/NEJMoa2015301.
  • Bloch EM , Shoham S , Casadevall A , et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest . 2020;130(6):2757–2765. doi:10.1172/JCI138745.
  • Mair-Jenkins J , Saavedra-Campos M , Baillie JK , et al ; Convalescent Plasma Study Group . The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis . 2015;211(1):80–90. doi:10.1093/infdis/jiu396.
  • Duan K , Liu B , Li C , et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA . 2020;117(17):9490–9496. doi:10.1073/pnas.2004168117.
  • Shen C , Wang Z , Zhao F , et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA . 2020;323(16):1582. doi:10.1001/jama.2020.4783.
  • Zhang B , Liu S , Tan T , et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest . 2020. doi:10.1016/j.chest.2020.03.039.
  • Li L , Zhang W , Hu Y , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA . 2020. doi:10.1001/jama.2020.10044.
  • Liu STH , Lin HM , Baine I , et al. Convalescent plasma treatment of severe COVID-19: a matched control study. medRxiv . 2020. doi:10.1101/2020.05.20.20102236.
  • Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ . 2020;368:m1256. doi:10.1136/bmj.m1256.
  • Arabi YM , Hajeer AH , Luke T , et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerging Infect Dis . 2016;22(9):1554–1561. doi:10.3201/eid2209.151164.
  • Wan Y , Shang J , Sun S , et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol . 2020;94(5):e02015–19. doi:10.1128/JVI.02015-19.
  • Casadevall A , Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest . 2020;130(4):1545–1548. doi:10.1172/JCI138003.
  • Conti P , Ronconi G , Caraffa A , et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents . 2020;34(2):1.
  • Li X , Geng M , Peng Y , Meng L , Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal . 2020;10(2):102–108. doi:10.1016/j.jpha.2020.03.001.
  • Tanaka T , Narazaki M , Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy . 2016;8(8):959–970. doi:10.2217/imt-2016-0020.
  • Assistance Publique–Hôpitaux de Paris . Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia. https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-patients-moderate-or-severe-covid-19. Published April 27, 2020. Accessed June 5, 2020.
  • BioSpace . Regeneron and Sanofi provide update on U.S. phase 2/3 adaptive-designed trial of Kevzara® (sarilumab) in hospitalized COVID-19 patients. https://www.biospace.com/article/releases/regeneron-and-sanofi-provide-update-on-u-s-phase-2-3-adaptive-designed-trial-of-kevzara-sarilumab-in-hospitalized-covid-19-patients. Published April 27, 2020. Accessed June 5, 2020.
  • Ni YN , Chen G , Sun J , Liang BM , Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care . 2019;23(1):99. doi:10.1186/s13054-019-2395-8.
  • Russell CD , Millar JE , Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet . 2020;395(10223):473–475. doi:10.1016/S0140-6736(20)30317-2.
  • Wu C , Chen X , Cai Y , et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med . 2020; e200994. doi:10.1001/jamainternmed.2020.0994.
  • Uccelli A , de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann N Y Acad Sci . 2015;1351(1):114–126. doi:10.1111/nyas.12815.
  • Golchin A , Seyedjafari E , Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev Rep . 2020;16(3):427–433. doi:10.1007/s12015-020-09973-w.
  • Lee JW , Fang X , Krasnodembskaya A , Howard JP , Matthay MA. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells . 2011;29(6):913–919. doi:10.1002/stem.643.
  • Shanmugaraj B , Siriwattananon K , Wangkanont K , Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol . 2020;38(1):10–18. doi:10.12932/AP-200220-0773.
  • Cockrell AS , Yount BL , Scobey T , et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol . 2016;2(2):16226. doi:10.1038/nmicrobiol.2016.226.
  • Han H , Yang L , Liu R , et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med . 2020. doi:10.1515/cclm-2020-0188.
  • Tang N , Li D , Wang X , Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost . 2020;18(4):844–847. doi:10.1111/jth.14768.
  • Guo T , Fan Y , Chen M , et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol . 2020. doi:10.1001/jamacardio.2020.1017.
  • Bikdeli B , Madhavan MV , Jimenez D , et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, anti-thrombotic therapy, and follow-up. J Am Coll Cardiol . 2020;75(23):2950–2973.
  • Gold JAW , Wong KK , Szablewski CM , et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19—Georgia, March 2020. MMWR Morb Mortal Wkly Rep . 2020;69(18):545–550. doi:10.15585/mmwr.mm6918e1.
  • Rello J , Storti E , Belliato M , Serrano R. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J . 2020;55(5):2001028. doi:10.1183/13993003.01028-2020.
  • Siddiqi HK , Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant . 2020;39(5):405–407. doi:10.1016/j.healun.2020.03.012.
  • Gilead Sciences . Gilead announces results from Phase 3 trial of remdesivir in patients with moderate COVID-19. https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19. Published June 1, 2020. Accessed June 5, 2020.
  • Faure E , Poissy J , Goffard A , et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One . 2014;9(2):e88716. doi:10.1371/journal.pone.0088716.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.